Are pathogen-reduced platelets as effective as standard platelets for the prevention of bleeding in people of any age requiring platelet transfusions?
In people with cancer who have a low platelet count due to their disease or its treatment, pathogen-reduced platelet transfusions increase risk of platelet refractoriness and platelet transfusion requirement (high-quality evidence) but probably do not effect all-cause mortality, risk of clinically significant or severe bleeding, or risk of a serious adverse event (moderate-quality evidence). There was insufficient evidence for people with other diagnoses.
Estcourt LJ, Malouf R, Murphy MF. Pathogen-Reduced Platelets for the Prevention of Bleeding in People of Any Age. JAMA Oncol. 2018;4(4):571–572. doi:https://doi.org/10.1001/jamaoncol.2017.5049
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: